New consensus reached to help tackle multidrug-resistant and extensively drug-resistant TB

New consensus statements have been developed to help tackle the growing threat of multidrug-resistant tuberculosis (TB) and extensively drug-resistant tuberculosis (TB).

Published online today (24 March 2014) in the European Respiratory Journal¸ the statements mark the first time that physicians who treat patients with multidrug- and extensively drug-resistant TB have reached a consensus on important areas of patient management where is inconclusive.

The World Health Organization (WHO) estimates that currently 450,000 new cases with MDR-TB occur each year. The majority of affected patients live in the WHO European Region.

As the emergence of these forms of the disease is fairly recent, clinical evidence is lacking and could be for many years to come. To help bridge this gap in knowledge, experts from the European-based TBNET network have provided harmonised answers to the key questions for the prevention, diagnosis, treatment and management of multidrug- and extensively drug-resistant TB.

Although some guidelines are available for the treatment of people with multidrug- and extensively drug-resistant TB, this is the first time that a large group of predominantly clinical experts have joined together to provide a consensus on the management of these conditions in Europe.

The consensus statements also include useful checklists with information on which examinations should be performed during the course of the treatment and what is necessary before discharging a patient from the hospital. The authors suggest that the document can be used as a point of reference for physicians across the continent.

Lead author, Professor Christoph Lange, Head of the Respiratory Infections Assembly at the European Respiratory Society, said: "These consensus statements provide very valuable support for physicians treating patients with these deadly conditions in all parts of Europe. The current management of patients with multidrug- and extensively drug-resistant TB is complex, very costly for healthcare systems and burdensome for those who are affected.

"We have harmonised individual expert opinions on the of multidrug- and extensively drug-resistant TB in adults and children to ensure that consensus is available where is still lacking. As clinicians we hope to improve the treatment of multidrug- and extensively drug-resistant TB and the life of our who suffer from these difficult-to-treat conditions."

More information: Management of patients with multidrug-resistant and extensively drug-resistant TB in Europe: TBNET consensus statement, DOI: 10.1183/09031936.00188313

add to favorites email to friend print save as pdf

Related Stories

India must stop 'irrational' TB treatments: MSF

Mar 23, 2014

India must stop its doctors prescribing "irrational" treatments to cure tuberculosis, medical humanitarian group Medecins Sans Frontieres said Saturday, warning the practice is increasing drug-resistant strains of the disease.

Recommended for you

Ebola in mind, US colleges screen some students

13 hours ago

University students from West Africa may be subject to extra health checks when they arrive to study in the United States as administrators try to insulate their campuses from the worst Ebola outbreak in ...

WHO: More Ebola cases in past week than any other

14 hours ago

The past week has seen the highest increase of Ebola cases since the outbreak in West Africa began, the World Health Organization said Friday, offering more evidence that the crisis is worsening.

User comments